Yousif Capital Management LLC Has $768,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Yousif Capital Management LLC reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,231 shares of the specialty pharmaceutical company’s stock after selling 425 shares during the quarter. Yousif Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $768,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SUPN. Stephens Investment Management Group LLC increased its stake in shares of Supernus Pharmaceuticals by 1.8% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after buying an additional 33,710 shares during the period. Pacer Advisors Inc. increased its position in Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares during the period. Geode Capital Management LLC raised its holdings in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares during the last quarter. Victory Capital Management Inc. lifted its position in Supernus Pharmaceuticals by 1.1% during the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock valued at $23,163,000 after purchasing an additional 7,833 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 14.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after purchasing an additional 91,354 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Down 1.1 %

Shares of Supernus Pharmaceuticals stock opened at $39.11 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $40.28. The business has a fifty day simple moving average of $37.54 and a 200 day simple moving average of $35.10. The stock has a market cap of $2.16 billion, a PE ratio of 36.55 and a beta of 0.90.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price objective on the stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.